Business Wire

Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis

Jaa

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). The decision to advance VX-659 and VX-445 into Phase 3 development was based on initial Phase 2 data, including new data from ongoing Phase 2 studies that showed mean absolute improvements in percent predicted forced expiratory volume in one second (ppFEV1) of up to 13.3 and 13.8 percentage points from baseline through four weeks of treatment for the triple combination regimens with VX-659 (400mg QD) or VX-445 (200mg QD), respectively, in people who have one F508del mutation and one minimal function mutation (F508del/Min). Regulatory discussions are ongoing to finalize the design of Phase 3 programs for VX-659 and VX-445. Upon completion of these discussions, Vertex plans to initiate a Phase 3 program in the first half of 2018 to evaluate VX-659 in triple combination with tezacaftor and ivacaftor. In addition, the company plans to initiate a Phase 3 program in mid-2018 to evaluate VX-445 in triple combination with tezacaftor and VX-561 as a once-daily regimen, pending additional data in the first half of 2018, including the Phase 2 data on the combination of VX-445, tezacaftor and VX-561. Vertex will discuss the Phase 2 data and Phase 3 development strategy during the company’s fourth-quarter and full-year 2017 financial results call for investors today, January 31, 2018 at 4:30 p.m. ET.

The triple combination regimens were generally well tolerated across both studies, and the majority of adverse events were mild to moderate in severity. Across the studies, the discontinuation rate due to adverse events was low.

“These results support the selection of both the VX-659 and VX-445 triple combination regimens and underscore the potential for these regimens to provide significant clinical benefits for up to 90 percent of people with CF,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. “We look forward to concluding our discussions with regulators and initiating Phase 3 development in the first half of the year, with the goal of bringing a triple combination regimen to patients as quickly as possible.”

“The triple combination data demonstrate the rapid advances we are making in treating the underlying cause of CF,” said Jennifer Taylor-Cousar, M.D., M.S.C.S., Associate Professor of Medicine and Pediatrics at National Jewish Health, Colorado, and co-chair of Vertex’s Triple Combination Steering Committee. “Together, all the Phase 2 data to date provide further evidence that the addition of a next-generation corrector to tezacaftor and ivacaftor has the potential to provide substantial clinical benefits to patients with one F508del and one minimal function mutation who don’t currently have a medicine to treat the underlying cause of their CF, as well as to provide additional benefits to patients with at least one F508del mutation who are already eligible for CFTR modulator therapies.”

About the Phase 3 Programs

Vertex is in the process of finalizing Phase 3 study designs for VX-659 and VX-445 with regulatory agencies, with the goal of bringing a potential triple combination regimen to patients as quickly as possible. Upon completion of these discussions, the company plans to begin the first Phase 3 program in the first half of 2018, which will initially evaluate VX-659 in triple combination with tezacaftor and ivacaftor in F508del/Min patients. A second study, also to begin in the first half of 2018, will evaluate this triple combination in people with two copies of the F508del mutation (F508del/F508del). Pending data from the ongoing Phase 2 study and completion of regulatory discussions, Vertex plans to initiate a Phase 3 program in mid-2018 to evaluate VX-445 with tezacaftor and VX-561 as a once-daily regimen in F508del/Min and F508del/F508del patients.

The VX-659 and VX-445 Phase 2 studies are both ongoing to evaluate triple combination regimens with tezacaftor and ivacaftor in F508del/F508del patients and triple combination regimens with tezacaftor and VX-561 as a once-daily regimen in F508del/Min patients. Vertex expects these data in the first half of 2018.

The decision to advance VX-659 and VX-445 into Phase 3 development was based on initial data from the Phase 2 studies of the company’s four next-generation correctors – VX-659, VX-445, VX-152 and VX-440, each in triple combination with tezacaftor and ivacaftor. Initial data from the ongoing VX-659 and VX-445 studies were announced today and are below. In July 2017, Vertex reported results from the VX-440 study as well as results from the 100mg and 200mg arms of the VX-152 study.

About the VX-659 Phase 2 Study

This ongoing randomized, double-blind Phase 2 study is evaluating VX-659 (80mg, 240mg and 400mg QD) in combination with tezacaftor and ivacaftor in two different groups of people with CF ages 18 and older – those who have one F508del mutation and one minimal function mutation (Part 1), and in those who have two copies of the F508del mutation (Part 2). Minimal function mutations are those that result in little-to-no functioning CFTR protein and are not responsive to ivacaftor, tezacaftor or the combination of tezacaftor and ivacaftor. Part 3 of the study is evaluating VX-659 in combination with tezacaftor and VX-561 as a potential once-daily triple combination regimen in F508del/Min patients. The primary objectives of the study are safety, tolerability and efficacy as assessed by mean absolute change in ppFEV1 from baseline. Secondary endpoints include change in sweat chloride and Cystic Fibrosis Questionnaire-Revised (CFQ-R). Data reported today are from Part 1 of the study. Parts 2 and 3 of the study are ongoing with data expected in the first half of 2018.

Safety Data: In Part 1 of the study, the triple combination regimen was generally well tolerated. The majority of adverse events were mild or moderate. Serious adverse events were reported in seven patients: three patients in the placebo group (2 with infective pulmonary exacerbations and 1 with decreased pulmonary function test) and four in the triple combination groups (3 with infective pulmonary exacerbations and 1 with influenza). None of these serious adverse events were considered related to treatment and none resulted in treatment discontinuation. The most common adverse events (>10%), regardless of treatment group, were cough, headache, oropharyngeal (throat) pain and sputum increased. There were no discontinuations due to adverse events. One patient interrupted treatment due to an adverse event in the triple combination treatment groups (rash). The rash resolved following interruption of treatment and the patient subsequently restarted and completed triple combination treatment without any further incidence.

Efficacy Data: Part 1 of the study evaluated the triple combination for four weeks in 63 patients who have one F508del mutation and one minimal function mutation (10 in placebo, 11 in VX-659 80mg, 20 in VX-659 240mg and 22 in VX-659 400mg). A summary of the within-group lung function and sweat chloride data is provided below:

   
VX-659 in F508del/Min Patients      

Mean Absolute Within-Group
Change From Baseline Through Day
29*

   

Mean Absolute Within-
Group Change in ppFEV 1
(percentage points)

   

Mean Absolute Within-
Group Change in Sweat
Chloride (mmol/L)

Triple placebo    

+0.3
(p=0.9053)

 

   

+2.9
(p=0.5338)

 

VX-659 (80mg QD) + tezacaftor
(100mg QD) + ivacaftor (150mg q12h)

   

+10.2
(p=0.0004)

 

   

-45.8
(p<0.0001)

 

VX-659 (240mg QD) + tezacaftor
(100mg QD) + ivacaftor (150mg q12h)

   

+11.6
(p<0.0001)

 

   

-43.7
(p<0.0001)

 

VX-659 (400mg QD) + tezacaftor

(100mg q12h) + ivacaftor (150mg q12h)

   

+13.3
(p<0.0001)

 

   

-51.4
(p<0.0001)

 

* all p-values are within group p-values based on mixed effect models; values expressed as
‘Through Day 29' are the average of Day 15 and Day 29 measures

 

A secondary endpoint in the study measured mean absolute change in the respiratory domain of CFQ-R,1 a validated patient-reported outcome measure, at Day 29. The mean absolute improvements for patients who received the triple combination were 24.6 points (VX-659 80mg), 19.8 points (VX-659 240mg) and 21.8 points (VX-659 400mg). The improvement for those who received placebo was 4.7 points.

About the VX-445 Phase 2 Study

This ongoing Phase 2 randomized, double-blind study evaluated the safety and tolerability of single and multiple ascending doses of VX-445 alone and in triple combination with tezacaftor and ivacaftor in healthy volunteers (Parts A, B and C). It is also evaluating the safety, tolerability and efficacy of VX-445 (50mg, 100mg and 200mg QD) in triple combination with tezacaftor and ivacaftor for four weeks in people with CF ages 18 and older who have one F508del mutation and one minimal function mutation (Part D) and in people who have two copies of the F508del mutation (Part E). Part F of the study is evaluating VX-445 in combination with tezacaftor and VX-561 as a potential once-daily triple combination regimen in F508del/Min patients. The primary objectives of the parts of the study in CF patients are safety, tolerability and efficacy as assessed by mean absolute change in ppFEV1 from baseline. Secondary endpoints include change in sweat chloride and CFQ-R. Data reported today are from Part D of the study. Parts E and F of the study are ongoing with data expected in the first half of 2018.

Safety Data: In Part D of the study, the triple combination regimen was generally well tolerated. The majority of adverse events were mild or moderate. Serious adverse events were reported in five patients: two patients in the placebo group (1 with hemoptysis and 1 with infective pulmonary exacerbation) and three patients in the triple combination groups (1 patient with infective pulmonary exacerbation, jugular vein thrombosis related to a central line, and distal intestinal obstruction syndrome; 1 patient with infective pulmonary exacerbation and influenza; and 1 patient with infective pulmonary exacerbation). None of these serious adverse events were considered related to treatment and none resulted in treatment discontinuation. The most common adverse events (>10%), regardless of treatment group, were cough, sputum increased, infective pulmonary exacerbation, hemoptysis, headache, nasal congestion, nausea, oropharyngeal pain and pyrexia. Two patients discontinued treatment due to adverse events in the triple combination treatment groups (1 patient with rash and 1 patient with increased bilirubin without associated elevations in transaminases) and none in the placebo group. Following treatment discontinuation, the rash resolved and the increased bilirubin returned to baseline. Two patients interrupted treatment due to adverse events in the triple combination groups (1 with constipation and 1 with increased bilirubin without associated elevations in transaminases); both events resolved when treatment was interrupted and both patients subsequently restarted and completed triple combination treatment without further incident.

Efficacy Data: Part D of the study evaluated the triple combination for four weeks in 65 patients who have one F508del mutation and one minimal function mutation (12 in combined placebo, 10 in VX-445 50mg, 22 in VX-445 100mg and 21 in VX-445 200mg). A summary of the within-group lung function and sweat chloride data is provided below:

 
VX-445 in F508del/Min Patients

Mean Absolute Within-Group
Change From Baseline Through Day
29*

   

Mean Absolute Within-
Group Change in ppFEV 1
(percentage points)

   

Mean Absolute Within-
Group Change in Sweat
Chloride (mmol/L)

Triple placebo    

0.0
(p=0.9943)

 

   

-2.2
(p=0.5804)

 

VX-445 (50mg QD) + tezacaftor
(100mg QD) + ivacaftor (150mg q12h)

   

+11.1
(p<0.0001)

 

   

-38.2
(p<0.0001)

 

VX-445 (100mg QD) + tezacaftor
(100mg QD) + ivacaftor (150mg q12h)

   

+7.8
(p<0.0001)

 

   

-33.2
(p<0.0001)

 

VX-445 (200mg QD) + tezacaftor
(100mg q12h) + ivacaftor (150mg q12h)

   

+13.8
(p<0.0001)

 

   

-39.1
(p<0.0001)

 

* all p-values are within group p-values based on mixed effect models; values expressed as
‘Through Day 29' are the average of Day 15 and Day 29 measures

 

A secondary endpoint in the study measured mean absolute change in the respiratory domain of CFQ-R1 at Day 29. The mean absolute improvements for patients who received the triple combination were 20.8 points (VX-445 50mg), 15.4 points (VX-445 100mg) and 25.7 points (VX-445 200mg). The improvement for those who received placebo was 4.2 points.

About the VX-152 Phase 2 Study

In July 2017, Vertex reported results for the 100mg and 200mg dose arms of the ongoing VX-152 Phase 2 study, which was also evaluating a 300mg dose of VX-152 in combination with tezacaftor and ivacaftor for two weeks in people who have one F508del mutation and one minimal function mutation and for four weeks in people who have two copies of the F508del mutation. Results from the 300mg arms of the VX-152 study were consistent with previously reported results, which showed a favorable safety profile, and rapid and significant increases in ppFEV1.

About CF

CF is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.

CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working or too few CFTR proteins at the cell surface. The defective function or absence of CFTR protein results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the mid-to-late 20s.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row. For additional information and the latest updates from the company, please visit www.vrtx.com.

Collaborative History with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT)

Vertex initiated its CF research program in 2000 as part of a collaboration with CFFT, the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. KALYDECO® (ivacaftor), ORKAMBI® (lumacaftor/ivacaftor), tezacaftor, VX-440, VX-152, VX-659 and VX-445 were discovered by Vertex as part of this collaboration.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Chodakewitz’s and Dr. Taylor-Cousar’s statements in the third and fourth paragraphs, respectively, and the information provided regarding (i) Vertex's selection of VX-659 and VX-445, (ii) additional data Vertex expects from its ongoing Phase 2 next-generation clinical trials, (iii) Vertex’s regulatory discussions to finalize the design of the Phase 3 development programs and (iv) the timing and design of Vertex’s Phase 3 development programs for VX-659 and VX-445. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release, and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include: (i) that Vertex could experience unforeseen delays in initiating its Phase 3 development programs to evaluate VX-659 and/or VX-445 as part of triple combination regimens, (ii) that the data set forth in this press release from the ongoing Phase 2 clinical trials may differ from data from additional parts of these Phase 2 clinical trials, (iii) that data from the Phase 3 development programs may not support approval of the company’s triple-combination regimens due to safety, efficacy or other reasons, and (iv) other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

1 CFQ-R results reported are based on a mixed effect model not adjusted for baseline CFQ-R

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, 617-341-6108
or
Eric Rojas, 617-961-7205
or
Zach Barber, 617-341-6470
or
Media:
mediainfo@vrtx.com
or
North America:
Megan Goulart, + 1-617-341-6992
or
Europe & Australia:
Rebecca Hunt, +44 7718 962 690

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Scientist.com Named One of America’s Ten Fastest-Growing Private Companies by Inc. Magazine16.8.2018 15:06Tiedote

Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it ranked no. 9 on Inc. magazine’s 2018 list of the 5,000 fastest-growing, privately owned companies in America. Scientist.com ranked no. 2 nationally in the Health category and no. 2 in the state of California. The San Diego-based company builds private marketplaces that connect life science research organizations with a global network of over 2,600 contract research organizations (CROs) and providers of scientific services. “Our mission is to empower and connect scientists worldwide and make it possible to cure all human diseases by 2050,” stated Kevin Lustig, Scientist.com’s CEO and Founder. “On Scientist.com, a single, highly trained scientist can run an entire drug discovery program from concept to clinic from his or her laptop without ever physically entering a laboratory.” The pharmaceutical industry spends about $150B a year on medical research and produces about 25 new medic

REN Using Kalkitech Sync Platform at Substations for Automated Disturbance Record Collection and Data Conversion16.8.2018 13:59Tiedote

Kalkitech, a global leader in solutions that simplify field data collection, protocol translation, and IT-OT transformation for utilities, announced Redes Energéticas Nacionais, S.A. (REN) has installed an automated file collection solution for its transmission network. It is used to automatically supply near-time data to an automated fault analysis and protection behavior software application. The solution utilizes Kalkitech’s SYNC 3000 Substation Data Concentrator in 64 out of a total of 82 substations located throughout the utility’s coverage area to collect data from multiple vendors and multiple types of protection relays which use several different communication protocols. SYNC 3000 collects disturbance record data using standard protocols like IEC 61850 and IEC 60870-5-103 as well as proprietary protocols like ABB SPA Bus and Alstom Courier. In the cases where data is not originally in a COMTRADE format, SYNC 3000 makes the required conversion into this standard format. An IEEE

FastForward.ai Launches “Ooredoo Next”, Myanmar’s New Digital Engagement Platform16.8.2018 13:15Tiedote

FastForward.ai launched today Ooredoo Next, the new digital engagement platform for Ooredoo Myanmar. Supported by FastForward NXTTM real-time API platform featuring artificial intelligence and machine learning, Ooredoo Next allows all mobile users in Myanmar to easily engage with Ooredoo brand inside Facebook Messenger using real-time automated answers. For Ooredoo Myanmar, FastForward.ai digital engagement platform enables efficient management of social media advertising campaigns, customer relationship management and monetization. Augie K. Fabela II, Co-Founder and CEO, FastForward.ai said: “We bring Silicon Valley user experience to the Telco world. We enable mobile operators to give their customers 100% control of their choices: they decide the services they want to use, how and when they want to use them." Romeo S. Ganescu, Co-Founder and Chief Product Officer, FastForward.ai said: “The future of mobile engagement lies inside social and messaging networks and our FastForward NXTTM

In the Wake of the Ongoing Floods in Kerala; UAE Exchange and Unimoni Waive Service Fee on Remittances to Kerala Chief Minister's Distress Relief Fund16.8.2018 12:30Tiedote

Leading money transfer, foreign exchange and payment solutions brands, UAE Exchange and Unimoni, have waived service fee on remittances to Kerala Chief Minister's Distress Relief Fund in the wake of the catastrophic floods that has ravaged the Indian state of Kerala. The initiative which enables the global Indian diaspora to contribute to the relief efforts, follows a personal contribution of two crore rupees made by the Group Chairman and noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty, to help those affected by the floods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180816005229/en/ Promoth Manghat, Executive Director, Finablr and Group CEO (Photo: AETOSWire) Promoth Manghat, Executive Director, Finablr and Group CEO, said, “As a committed corporate citizen, who firmly believes in helping communities in times of need, it was our responsibility to do all that is in our power to aid the peopl

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00Tiedote

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05Tiedote

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme